GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » Debt-to-Revenue

MYND Life Sciences (XCNQ:MYND) Debt-to-Revenue : N/A (As of Jul. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

MYND Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was C$3.00 Mil. MYND Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was C$0.00 Mil. MYND Life Sciences's annualized Revenue for the quarter that ended in Jul. 2024 was C$0.00 Mil.

MYND Life Sciences Debt-to-Revenue Historical Data

The historical data trend for MYND Life Sciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences Debt-to-Revenue Chart

MYND Life Sciences Annual Data
Trend Oct21 Oct22 Oct23
Debt-to-Revenue
N/A N/A N/A

MYND Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of MYND Life Sciences's Debt-to-Revenue

For the Biotechnology subindustry, MYND Life Sciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MYND Life Sciences's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MYND Life Sciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where MYND Life Sciences's Debt-to-Revenue falls into.


MYND Life Sciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

MYND Life Sciences's Debt-to-Revenue for the fiscal year that ended in Oct. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3 + 0) / N/A
=N/A

MYND Life Sciences's annualized Debt-to-Revenue for the quarter that ended in Jul. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jul. 2024) Revenue data.

MYND Life Sciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

MYND Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » Debt-to-Revenue
Comparable Companies
TSXV:IBO TSXV:QPT XCNQ:LOBE TSX:APLI XCNQ:ASEP TSXV:XRTX XCNQ:AWKN XCNQ:MBIO XCNQ:GTTX TSXV:MRVL VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
MYNDF:USA
Address
105-2248 Elgin Avenue, Port Coquitlam, BC, CAN, V3C 2B2
Website
https://www.myndsciences.com
MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.